Fortrea Holdings (FTRE) Net Margin (2022 - 2026)

Fortrea Holdings (FTRE) posted Net Margin of 3.71% for Q1 2026, down 303.49% on a QoQ basis from 1.82% in Q4 2024.

Fortrea Holdings (FTRE) Net Margin (2022 - 2026) Analysis & Trends

Fortrea Holdings' Net Margin history runs 4 years deep, the most recent figure standing at 3.71% for Q1 2026.

Quarterly Net Margin changed N/A year-over-year to 3.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.87% (up 46.0% YoY) and the FY2024 annual result came in at 2.11%, down 234.0% from the prior year.
Net Margin was 3.71% for Q1 2026 at Fortrea Holdings, down from 1.82% in the prior quarter.
Across five years, Net Margin topped out at 8.37% in Q2 2022 and bottomed at 5.9% in Q2 2024.
A 4-year average of 0.18% and a median of 0.27% in 2023 frame the typical range for Net Margin.
Annual changes were most pronounced in 2023 — Net Margin sank 766 bps — and 2024, when it soared 265 bps.
Fortrea Holdings' Net Margin stood at 2.71% in 2022, then jumped by 69 bps to 0.83% in 2023, then jumped by 319 bps to 1.82% in 2024, then sank by 303 bps to 3.71% in 2026.
Business Quant data shows FTRE's Net Margin at 3.71% in Q1 2026, 1.82% in Q4 2024, and 1.39% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Fortrea Holdings	1.83 Bn	1.68 Bn	123.60 Mn	-3.71%

Download Data